GP 20101
Alternative Names: GP-20101Latest Information Update: 22 Sep 2022
At a glance
- Originator GEROPHARM
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 14 Sep 2022 GP 20101 is available for licensing as of 14 Sep 2022. https://geropharm.com/ (GEROPHARM website, September 2022)
- 14 Sep 2022 Early research in Unspecified in Russia (unspecified route) prior to September 2022 (GEROPHARM pipeline, September 2022)